MedTrace Logo

Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress

NCT04541654 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2026-03-27

No results posted yet for this study

Summary

The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism).

Conditions

  • Li-Fraumeni Syndrome
  • TP53 Gene Mutation
  • Hereditary Cancer Syndrome
  • Clonal Hematopoiesis
  • Mosaicism

Interventions

GENETIC

Data and Specimen Collection

* Provide research team and access to relevant medical records * Answer short questionnaires periodically * Consider consenting to other optional parts of the research such as: * Providing up to 3 tubes (15ml) of blood at or near the time of consent, as approved by treating physician (optional). * Provide a saliva sample (optional). * Provide eyebrow hairs for analysis of DNA from the bulb (15-20 eyebrow plucks) (optional). * Provide permission for obtainment of stored tissue specimens from cancer or pre-cancer surgeries or biopsies from the pathology departments where they have been stored (optional). * Consider inviting relatives to join the study (optional).

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    collaborator OTHER

  • Baylor College of Medicine

    collaborator OTHER

  • Dana-Farber Cancer Institute

    lead OTHER

Principal Investigators

  • Judy E Garber, MD, MPH · Dana-Farber Cancer Institute

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-15
Primary Completion
2030-12-31
Completion
2032-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04541654 on ClinicalTrials.gov